mTOR activation as a mechanism for sex differences in vaccine-induced immunity
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1F32AI186453-01
Grant search
Key facts
Disease
UnspecifiedStart & end year
20242025Known Financial Commitments (USD)
$74,764Funder
National Institutes of Health (NIH)Principal Investigator
POSTDOCTORAL FELLOW Laura St ClairResearch Location
United States of AmericaLead Research Institution
JOHNS HOPKINS UNIVERSITYResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Project Summary Biological sex has profound effects on the effectiveness of vaccines that protect against pathogens of pandemic potential, including influenza A viruses. Following influenza vaccination, females of reproductive ages (18-49 years) produce greater antiviral antibody responses than age-matched males, which correlates with greater estradiol (E2) concentrations in females. How estrogens drive greater B cell activation and antibody production after vaccination is not known. Estrogen receptor signaling in B cells might alter metabolic signaling to cause sex differences in vaccine-induced immunity. Activation of mTOR, in particular, and a switch towards β-oxidation as a primary energy source has been identified as indispensable for B cell proliferation, differentiation, and antibody production. Prior studies have demonstrated that females show greater preference for the use β- oxidation for energy production when under high energy demand. Thus, I hypothesized that differential activation of mTOR and downstream utilization of lipids for β-oxidation may be a potential mediator of sex differences in vaccine-induced immunity. My preliminary data show that after H1N1 vaccination in mice, adult females have greater activation of mTOR and mTOR-related proteins in splenic B cells than age-matched males. I hypothesize that greater mTOR activation in B cells from females is partially regulated by E2 through an ERα-mTOR feedback loop. My central hypothesis is that sex steroid signaling causes distinct metabolic signatures in B cells and that differential regulation of mTOR is the central mechanism governing sex-specific differences in vaccine-mediated humoral immunity. In Aim 1, I will test whether manipulation of mTOR and selected downstream proteins using small molecule agonist and antagonist can reverse sex differences in immune responses using a mouse model of influenza vaccination. I will use immunofluorescence assays and seahorse analysis of mitochondrial respiration to dissect sex differences in metabolic activation in B cells following vaccination, which will be correlated with measures of protective immunity. In Aim 2, I will examine the effects of sex chromosome complement and sex steroid signaling on both mTOR activation and metabolic activation of B cells. Through these experiments, I seek to define the cellular mechanisms mediating sex differences in vaccine-induced immunity. These results have significant translational application. As a fellow, the research that I have outlined is crucial to extend my training in animal models, viral immunology, sex-based biology, and biomedical research to refine my expertise in using metabolomics-based approaches to gain mechanistic insight into biological phenomena.